Blockchain Registration Transaction Record

NanoViricides Gains Approval for Ebola Phase II Trial with Oral Gummies

NanoViricides gains DRC approval for Phase II Ebola trial of NV-387 Oral Gummies, a unique oral treatment for Bundibugyo ebolavirus. Learn about this broad-spectrum antiviral and its potential impact.

NanoViricides Gains Approval for Ebola Phase II Trial with Oral Gummies

This news matters because the approval of NV-387 Oral Gummies for a Phase II Ebola trial introduces a potentially game-changing oral treatment for a deadly virus, addressing critical logistical challenges in outbreak zones where IV treatments are impractical. If successful, it could provide a scalable, easy-to-administer therapy for Ebola, saving lives in resource-limited regions and reinforcing NanoViricides’ broad-spectrum antiviral platform against future pandemics.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x6d09cdd294e9533aacdd501479bd9217186b448b29afd9dcd5ce9bfbb014ce5d
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintroam0_rX-76e6367167295a34535ace0651f67bf3